Oxbridge Re Holdings Limited Reports First Quarter 2024 Results
May 09, 2024 16:01 ET
|
Oxbridge Re Holdings Limited
GRAND CAYMAN, Cayman Islands, May 09, 2024 (GLOBE NEWSWIRE) -- Oxbridge Re Holdings Limited (NASDAQ: OXBR), (the “Company”), which together with its subsidiaries is engaged in the business of...
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
May 09, 2024 16:01 ET
|
Dianthus Therapeutics, Inc.
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing, with top-line results anticipated in 2H’25 Building a neuromuscular franchise with DNTH103; Phase 2 trial in Multifocal Motor...
Urbana Corporation Has Filed 2024 First Quarter Interim Financial Statements
May 09, 2024 16:01 ET
|
Urbana Corporation
/NOT FOR DISTRIBUTION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE U.S./ TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Urbana Corporation (TSX & CSE: URB & URB.A) Urbana Corporation...
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024 16:01 ET
|
Invivyd
Launched PEMGARDA™ in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and adolescents with moderate-to-severe immune compromiseReported interim exploratory COVID-19 clinical...
American Shared Hospital Services Announces Closing of Acquisition of 60% Majority Interest in Three Radiation Therapy Cancer Centers in Rhode Island
May 09, 2024 16:01 ET
|
American Shared Hospital Services
American Shared Hospital Services Announces Closing of Acquisition of 60% Majority Interest in Three Radiation Therapy Cancer Centers in Rhode Island
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 16:01 ET
|
Coherus BioSciences, Inc.
– Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million...
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 16:01 ET
|
eFFECTOR Therapeutics, Inc.
Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway...
First Quantum Minerals Announces Voting Results for the Election of Directors
May 09, 2024 16:01 ET
|
First Quantum Minerals Ltd.
TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- First Quantum Minerals Ltd. (“First Quantum” or “the Company”) (TSX: FM) announced that the nominees listed in the Management Information Circular for the...
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 09, 2024 16:01 ET
|
Fate Therapeutics, Inc.
First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease Enrollment...
Athabasca Oil Corporation Announces Results from 2024 Annual Shareholder Meeting
May 09, 2024 16:00 ET
|
Athabasca Oil Corporation
CALGARY, Alberta, May 09, 2024 (GLOBE NEWSWIRE) -- Athabasca Oil Corporation (TSX: ATH) (“Athabasca” or the “Company”) announces that all matters presented for approval at the Annual General and...
- June 15, 2024 08:57 ET MULTIMEDIA UPDATE -- Rygen Technologies Launches Next-Gen Supply Chain Solution: AI-enabled TMS
- June 14, 2024 21:21 ET Pik'r Range Picking Robot Enhances U.S. Open Experience at Pinehurst